Haid et al. have identified a flavenoid that inhibits post-attachment entry of HCV and prevents infection of primary human hepatocytes. The previously unreported antiviral activity of ladanein (BJ486K) is effective against all major HCV genotypes. A synergistic effect was achieved by combining ladanein with ciclosporin—as such, the authors believe that flavanoid derivatives have potential as part of combined treatment, for example, in transplant recipients.